Leveraging Commercial and Quantitative Expertise
A public biotech company (market cap > $2B) is augmenting their strategy of discovering new antibodies with an early stage licensing strategy. They wish to use their clinical knowledge of antibody technology to select early licensing opportunities that they will develop to PoC and then re-license to larger partners. The organization has deep scientific knowledge, but neither commercial products nor personnel.
© 2020 SOURCE EXPLORER®. All rights reserved.